{"id":46597,"date":"2022-12-08T11:01:42","date_gmt":"2022-12-08T09:01:42","guid":{"rendered":"https:\/\/newserver.fyb.de\/bayern-kapital-total-of-eur-51-million-for-tricares\/"},"modified":"2022-12-08T15:54:13","modified_gmt":"2022-12-08T13:54:13","slug":"bayern-kapital-total-of-eur-51-million-for-tricares","status":"publish","type":"post","link":"https:\/\/www.fyb.de\/en\/bayern-kapital-total-of-eur-51-million-for-tricares\/","title":{"rendered":"Bayern Kapital: Insgesamt EUR 51 Mio. for TRiCares"},"content":{"rendered":"
\n

Landshut\/Munich\/Paris \u2014 Bayern Kapi\u00adtal is taking a signi\u00adfi\u00adcant million euro stake in Paris-based TRiCa\u00adres SAS, whose wholly owned subsi\u00addiary, TRiCa\u00adres GmbH of Asch\u00adheim near Munich, employs around 20 highly quali\u00adfied staff in Bava\u00adria, using resour\u00adces from the Bava\u00adria 2 growth fund. The German-French MedTech start-up is deve\u00adlo\u00adping the medi\u00adcal device Topaz, a cathe\u00adter-based heart valve repla\u00adce\u00adment system, to better treat severe tricu\u00adspid regurgitation.<\/p>\n

The invest\u00adment was made in the course of the second closing of a tran\u00adsac\u00adtion alre\u00adady announ\u00adced in Septem\u00adber. Series C finan\u00adcing round with a total volume of EUR 47 million<\/strong>whose inves\u00adtors include, in addi\u00adtion to the lead inves\u00adtor 415 Capi\u00adtal <\/strong>also Go Capi\u00adtal, Karista, Credit Mutuel Inno\u00adva\u00adtion, Welling\u00adton Part\u00adners, Andera Part\u00adners, Biomed\u00adin\u00advest<\/strong> as well as a Consor\u00adtium of private inves\u00adtors<\/strong> around the company foun\u00adder Pascal Lim.<\/p>\n

Heart valve dise\u00adase is one of the most serious heart dise\u00ada\u00adses, affec\u00adting more than 12.7 million pati\u00adents in Europe and many more world\u00adwide. Although mini\u00admally inva\u00adsive cathe\u00adter-based solu\u00adti\u00adons for the treat\u00adment of aortic and mitral valve dise\u00adase have been deve\u00adlo\u00adped in recent years, none have been deve\u00adlo\u00adped speci\u00adfi\u00adcally for the tricu\u00adspid valve. Tricu\u00adspid valve regur\u00adgi\u00adta\u00adtion is a common and serious condi\u00adtion for which open-heart surgery and sympto\u00adma\u00adtic phar\u00adma\u00adco\u00adlo\u00adgic treat\u00adment are the stan\u00addard treat\u00adment opti\u00adons. Howe\u00adver, due to the high morta\u00adlity risk, open-heart surgery is ruled out for more than 99% of dise\u00ada\u00adsed indi\u00advi\u00addu\u00adals \u2014 the average survi\u00adval time for pati\u00adents without surgi\u00adcal treat\u00adment is only 2.2 years.<\/p>\n

TRiCa\u00adres\u2019 Topaz trans\u00adfe\u00admo\u00adral heart valve repla\u00adce\u00adment system promi\u00adses to be a medi\u00adcal mile\u00adstone in the treat\u00adment of tricu\u00adspid regur\u00adgi\u00adta\u00adtion. The inno\u00adva\u00adtive medi\u00adcal device was deve\u00adlo\u00adped speci\u00adfi\u00adcally for pati\u00adents with severe tricu\u00adspid regur\u00adgi\u00adta\u00adtion to avoid risky open heart surgery. Topaz is the result of a French-German colla\u00adbo\u00adra\u00adtion and is implan\u00adted from the pati\u00aden\u00adt\u2019s femo\u00adral vein in a lower-risk mini\u00admally inva\u00adsive proce\u00addure. It is speci\u00adfi\u00adcally desi\u00adgned to fit the anatomy of the tricu\u00adspid valve for easy posi\u00adtio\u00adning and high func\u00adtion\u00ada\u00adlity. The pros\u00adpects of pati\u00adents for whom there are no other treat\u00adment opti\u00adons can thus be signi\u00adfi\u00adcantly improved.<\/p>\n

The Company plans to use the new funding from the comple\u00adted Series C round initi\u00adally to cover the costs of the curr\u00adently ongo\u00ading first-in-man clini\u00adcal trial of Topaz (TRICURE FIH trial) in Belgium, as well as for the poten\u00adtial submis\u00adsion of the same in other Euro\u00adpean count\u00adries. Howe\u00adver, the new capi\u00adtal will prima\u00adrily be inves\u00adted in the further deve\u00adlo\u00adp\u00adment of the product and to conduct a regis\u00adtra\u00adtion trial in the USA. To this end, TRiCa\u00adres 2023 is initia\u00adting an early feasi\u00adbi\u00adlity study in five U.S. centers.<\/p>\n

Helmut Strau\u00adbin\u00adger, Presi\u00addent and CEO of TRiCa\u00adres<\/strong>, says: \u201cThe successful finan\u00adcing reflects the enorm\u00adous poten\u00adtial of the Topaz heart valve repla\u00adce\u00adment system, our conti\u00adnuous progress in its deve\u00adlo\u00adp\u00adment and the great confi\u00addence of our inves\u00adtors. We are doing ever\u00ady\u00adthing we can to prove our very good results to date in clini\u00adcal trials in other Euro\u00adpean count\u00adries and also in the U.S., so that we can then offer this much-needed solu\u00adtion to all pati\u00adents suffe\u00adring from severe tricu\u00adspid regurgitation.\u201d<\/p>\n

Bava\u00adria\u2019s Minis\u00adter of Econo\u00admic Affairs Hubert Aiwan\u00adger <\/strong>adds: \u201cToge\u00adther with the Euro\u00adpean Invest\u00adment Bank (EIB), we have endo\u00adwed the Bava\u00adria 2 Growth Fund with 165 million euros to support high-tech start-ups in the deve\u00adlo\u00adp\u00adment phase. One of our goals here is to ensure that such compa\u00adnies conti\u00adnue to remain in Bava\u00adria and do not have to migrate due to a lack of funding. The exam\u00adple of TRiCa\u00adres shows how dyna\u00admic and inno\u00adva\u00adtive our Bava\u00adrian ecosys\u00adtem for start-ups is.\u201d<\/p>\n

\u201cTricu\u00adspid valve surge\u00adries are among the riskiest cura\u00adtive proce\u00addu\u00adres, with a large propor\u00adtion of affec\u00adted pati\u00adents deemed unsui\u00adta\u00adble due to high morta\u00adlity rates,\u201d explains Dr. Georg Ried, Mana\u00adging Direc\u00adtor of Bayern Kapi\u00adtal. <\/strong>\u201cWith Topaz, TRiCa\u00adres is deve\u00adlo\u00adping an inno\u00adva\u00adtive product with excel\u00adlent poten\u00adtial to fill this major gap in the treat\u00adment of valvu\u00adlar heart dise\u00adase. We are very plea\u00adsed to support TRiCa\u00adres on its further course towards market approval.\u201d<\/p>\n

\u201cWe believe that the tech\u00adno\u00adlogy deve\u00adlo\u00adped by TRiCa\u00adres has the poten\u00adtial to estab\u00adlish itself as the gold stan\u00addard in the treat\u00adment of pati\u00adents with tricu\u00adspid regur\u00adgi\u00adta\u00adtion and to restore the quality of life of milli\u00adons of pati\u00adents in the long term,\u201d commen\u00adted Frede\u00adrik Groe\u00adne\u00adwe\u00adgen, mana\u00adging part\u00adner of 415 Capi\u00adtal.<\/strong> \u201cWe are impres\u00adsed with the initial clini\u00adcal cases with the Topaz system and look forward to helping the team bring this novel therapy to pati\u00adents in the U.S. and Europe.\u201d<\/p>\n

About TRiCa\u00adres<\/strong>
\nTRiCa\u00adres is a medi\u00adcal device start-up based in Paris and Munich with a vision to bring a trans\u00adfe\u00admo\u00adral tricu\u00adspid valve repla\u00adce\u00adment system to market. This is inten\u00added to help pati\u00adents with severe tricu\u00adspid regur\u00adgi\u00adta\u00adtion (TI) without the need for open heart surgery. TRiCa\u00adres\u2019 expe\u00adri\u00aden\u00adced team is supported by leading Euro\u00adpean life science venture capi\u00adtal firms 415 Capi\u00adtal, Andera Part\u00adners, Bayern Kapi\u00adtal, BioMed\u00adPart\u00adners, Credit Mutuel Inno\u00adva\u00adtion, GoCa\u00adpi\u00adtal, Karista and Welling\u00adton Partners.
\nwww.tricares.com<\/a><\/p>\n

About Bayern Kapital<\/strong>
\nBayern Kapi\u00adtal GmbH, based in Lands\u00adhut, is the venture\/growth capi\u00adtal company of the Free State of Bava\u00adria. It accom\u00adpa\u00adnies inno\u00adva\u00adtive high-tech compa\u00adnies in the Free State through various growth phases, from seed to later stage, with equity capi\u00adtal in the amount of 0.25 to 25 million euros. Bayern Kapi\u00adtal often fills gaps in the VC sector in proven consor\u00adtium constel\u00adla\u00adti\u00adons with private inves\u00adtors (busi\u00adness angels, family offices and corpo\u00adrate ventures).<\/p>\n

Bayern Kapi\u00adtal mana\u00adges specia\u00adli\u00adzed invest\u00adment funds with a volume of around 700 million euros. Since its foun\u00adda\u00adtion in 1995 on the initia\u00adtive of the state govern\u00adment, the wholly owned subsi\u00addiary of LfA F\u00f6rder\u00adbank Bayern has so far inves\u00adted around 400 million euros of its own equity capi\u00adtal in around 300 start-ups and scale-ups in sectors such as life scien\u00adces, soft\u00adware & IT, mate\u00adri\u00adals & new mate\u00adri\u00adals, nano\u00adtech\u00adno\u00adlogy and envi\u00adron\u00admen\u00adtal tech\u00adno\u00adlogy. As a result, more than 8,000 jobs have been perma\u00adnently crea\u00adted in Bava\u00adria in sustainable compa\u00adnies. The active port\u00adfo\u00adlio curr\u00adently compri\u00adses over 80 companies.<\/p>\n

Examp\u00adles of nume\u00adrous ground\u00adbrea\u00adking success stories that Bayern Kapi\u00adtal has been invol\u00adved in early on include EOS (today the worl\u00add\u2019s leading tech\u00adno\u00adlogy provi\u00adder in indus\u00adtrial 3D prin\u00adting of metals and plas\u00adtics), Proglove, Fazua, SimS\u00adcale, Scom\u00adpler, egym, Parcel\u00adlab, Cobrai\u00adner, Quan\u00adtum Systems, Casavi, Theva, Riskme\u00adthods, Tubu\u00adlis, Cata\u00adlym, Immu\u00adnic, Sirion and many more.
\nwww.bayernkapital.de<\/a><\/p>\n<\/div>\n

\n
<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Landshut\/Munich\/Paris \u2014 Bayern Kapi\u00adtal is taking a signi\u00adfi\u00adcant million euro stake in Paris-based TRiCa\u00adres SAS, whose wholly owned subsi\u00addiary, TRiCa\u00adres GmbH of Asch\u00adheim near Munich, employs around 20 highly quali\u00adfied staff in Bava\u00adria, using resour\u00adces from the Bava\u00adria 2 growth fund. The German-French MedTech start-up is deve\u00adlo\u00adping the medi\u00adcal device Topaz, a cathe\u00ad\u00adter-based heart valve [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":46594,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1366,1368,1369,1372,1373],"tags":[],"class_list":["post-46597","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-news-en","category-lawyers-tax-consultants-auditors","category-investors","category-consultant","category-venture-capital-en"],"yoast_head":"\nBayern Kapital: Insgesamt EUR 51 Mio. for TRiCares - FYB Financial Yearbook<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fyb.de\/en\/bayern-kapital-total-of-eur-51-million-for-tricares\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bayern Kapital: Insgesamt EUR 51 Mio. for TRiCares - FYB Financial Yearbook\" \/>\n<meta property=\"og:description\" content=\"Landshut\/Munich\/Paris \u2014 Bayern Kapi\u00adtal is taking a signi\u00adfi\u00adcant million euro stake in Paris-based TRiCa\u00adres SAS, whose wholly owned subsi\u00addiary, TRiCa\u00adres GmbH of Asch\u00adheim near Munich, employs around 20 highly quali\u00adfied staff in Bava\u00adria, using resour\u00adces from the Bava\u00adria 2 growth fund. The German-French MedTech start-up is deve\u00adlo\u00adping the medi\u00adcal device Topaz, a cathe\u00adter-based heart valve […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fyb.de\/en\/bayern-kapital-total-of-eur-51-million-for-tricares\/\" \/>\n<meta property=\"og:site_name\" content=\"FYB Financial Yearbook\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-08T09:01:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-12-08T13:54:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fyb.de\/wp-content\/uploads\/2022\/12\/htc-herz-580x333-1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"580\" \/>\n\t<meta property=\"og:image:height\" content=\"333\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Tatjana Anderer\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatjana Anderer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.fyb.de\/en\/bayern-kapital-total-of-eur-51-million-for-tricares\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/bayern-kapital-total-of-eur-51-million-for-tricares\/\"},\"author\":{\"name\":\"Tatjana Anderer\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\"},\"headline\":\"Bayern Kapital: Insgesamt EUR 51 Mio. for TRiCares\",\"datePublished\":\"2022-12-08T09:01:42+00:00\",\"dateModified\":\"2022-12-08T13:54:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/bayern-kapital-total-of-eur-51-million-for-tricares\/\"},\"wordCount\":1013,\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/bayern-kapital-total-of-eur-51-million-for-tricares\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2022\/12\/htc-herz-580x333-1.jpeg\",\"articleSection\":[\"General\",\"Featured\",\"News\",\"Lawyers, tax consultants, auditors\",\"Investors\",\"Consultant\",\"Venture Capital\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.fyb.de\/en\/bayern-kapital-total-of-eur-51-million-for-tricares\/\",\"url\":\"https:\/\/www.fyb.de\/en\/bayern-kapital-total-of-eur-51-million-for-tricares\/\",\"name\":\"Bayern Kapital: Insgesamt EUR 51 Mio. for TRiCares - FYB Financial Yearbook\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/bayern-kapital-total-of-eur-51-million-for-tricares\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/bayern-kapital-total-of-eur-51-million-for-tricares\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2022\/12\/htc-herz-580x333-1.jpeg\",\"datePublished\":\"2022-12-08T09:01:42+00:00\",\"dateModified\":\"2022-12-08T13:54:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.fyb.de\/en\/bayern-kapital-total-of-eur-51-million-for-tricares\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.fyb.de\/en\/bayern-kapital-total-of-eur-51-million-for-tricares\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/bayern-kapital-total-of-eur-51-million-for-tricares\/#primaryimage\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2022\/12\/htc-herz-580x333-1.jpeg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2022\/12\/htc-herz-580x333-1.jpeg\",\"width\":580,\"height\":333},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.fyb.de\/en\/bayern-kapital-total-of-eur-51-million-for-tricares\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.fyb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bayern Kapital: Insgesamt EUR 51 Mio. for TRiCares\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.fyb.de\/en\/#website\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"name\":\"FYB Financial Yearbook\",\"description\":\"For Your Business\",\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.fyb.de\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\",\"name\":\"FYB Financial Yearbook\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"caption\":\"FYB Financial Yearbook\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\",\"name\":\"Tatjana Anderer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"caption\":\"Tatjana Anderer\"},\"description\":\"Gr\u00fcnderin des FYB-Verlag\",\"sameAs\":[\"http:\/\/neu.fyb.de\"],\"url\":\"https:\/\/www.fyb.de\/en\/author\/tanderer\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bayern Kapital: Insgesamt EUR 51 Mio. for TRiCares - FYB Financial Yearbook","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fyb.de\/en\/bayern-kapital-total-of-eur-51-million-for-tricares\/","og_locale":"en_US","og_type":"article","og_title":"Bayern Kapital: Insgesamt EUR 51 Mio. for TRiCares - FYB Financial Yearbook","og_description":"Landshut\/Munich\/Paris \u2014 Bayern Kapi\u00adtal is taking a signi\u00adfi\u00adcant million euro stake in Paris-based TRiCa\u00adres SAS, whose wholly owned subsi\u00addiary, TRiCa\u00adres GmbH of Asch\u00adheim near Munich, employs around 20 highly quali\u00adfied staff in Bava\u00adria, using resour\u00adces from the Bava\u00adria 2 growth fund. The German-French MedTech start-up is deve\u00adlo\u00adping the medi\u00adcal device Topaz, a cathe\u00adter-based heart valve […]","og_url":"https:\/\/www.fyb.de\/en\/bayern-kapital-total-of-eur-51-million-for-tricares\/","og_site_name":"FYB Financial Yearbook","article_published_time":"2022-12-08T09:01:42+00:00","article_modified_time":"2022-12-08T13:54:13+00:00","og_image":[{"width":580,"height":333,"url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2022\/12\/htc-herz-580x333-1.jpeg","type":"image\/jpeg"}],"author":"Tatjana Anderer","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tatjana Anderer","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fyb.de\/en\/bayern-kapital-total-of-eur-51-million-for-tricares\/#article","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/bayern-kapital-total-of-eur-51-million-for-tricares\/"},"author":{"name":"Tatjana Anderer","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce"},"headline":"Bayern Kapital: Insgesamt EUR 51 Mio. for TRiCares","datePublished":"2022-12-08T09:01:42+00:00","dateModified":"2022-12-08T13:54:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fyb.de\/en\/bayern-kapital-total-of-eur-51-million-for-tricares\/"},"wordCount":1013,"publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"image":{"@id":"https:\/\/www.fyb.de\/en\/bayern-kapital-total-of-eur-51-million-for-tricares\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2022\/12\/htc-herz-580x333-1.jpeg","articleSection":["General","Featured","News","Lawyers, tax consultants, auditors","Investors","Consultant","Venture Capital"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.fyb.de\/en\/bayern-kapital-total-of-eur-51-million-for-tricares\/","url":"https:\/\/www.fyb.de\/en\/bayern-kapital-total-of-eur-51-million-for-tricares\/","name":"Bayern Kapital: Insgesamt EUR 51 Mio. for TRiCares - FYB Financial Yearbook","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fyb.de\/en\/bayern-kapital-total-of-eur-51-million-for-tricares\/#primaryimage"},"image":{"@id":"https:\/\/www.fyb.de\/en\/bayern-kapital-total-of-eur-51-million-for-tricares\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2022\/12\/htc-herz-580x333-1.jpeg","datePublished":"2022-12-08T09:01:42+00:00","dateModified":"2022-12-08T13:54:13+00:00","breadcrumb":{"@id":"https:\/\/www.fyb.de\/en\/bayern-kapital-total-of-eur-51-million-for-tricares\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fyb.de\/en\/bayern-kapital-total-of-eur-51-million-for-tricares\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/bayern-kapital-total-of-eur-51-million-for-tricares\/#primaryimage","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2022\/12\/htc-herz-580x333-1.jpeg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2022\/12\/htc-herz-580x333-1.jpeg","width":580,"height":333},{"@type":"BreadcrumbList","@id":"https:\/\/www.fyb.de\/en\/bayern-kapital-total-of-eur-51-million-for-tricares\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fyb.de\/en\/"},{"@type":"ListItem","position":2,"name":"Bayern Kapital: Insgesamt EUR 51 Mio. for TRiCares"}]},{"@type":"WebSite","@id":"https:\/\/www.fyb.de\/en\/#website","url":"https:\/\/www.fyb.de\/en\/","name":"FYB Financial Yearbook","description":"For Your Business","publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fyb.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.fyb.de\/en\/#organization","name":"FYB Financial Yearbook","url":"https:\/\/www.fyb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","caption":"FYB Financial Yearbook"},"image":{"@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce","name":"Tatjana Anderer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","caption":"Tatjana Anderer"},"description":"Gr\u00fcnderin des FYB-Verlag","sameAs":["http:\/\/neu.fyb.de"],"url":"https:\/\/www.fyb.de\/en\/author\/tanderer\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/46597","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/comments?post=46597"}],"version-history":[{"count":3,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/46597\/revisions"}],"predecessor-version":[{"id":47023,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/46597\/revisions\/47023"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media\/46594"}],"wp:attachment":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media?parent=46597"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/categories?post=46597"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/tags?post=46597"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}